Neovacs S.A. (ENXTPA: ALNEV)
Health Care · Biotechnology · FR
€0.66
+7.81% today · -100.0% 1Y
Neovacs S.A. (ENXTPA: ALNEV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $113.64K and employs 16 people.
Over the last twelve months the share price has lost 100.0%, trading between 0.62 and 8.50K.
Tweenvest scores Neovacs S.A. across four factors: quality 21/100, value 57/100. Its strongest factor is value.
ALNEV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $113.64K
- Revenue (TTM)
- $234.02K
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -1,227.82
- 52-week high
- €8,500.00
- 52-week low
- €0.62
- Avg volume (3M)
- —
- Shares outstanding
- 159.06K
- Employees
- 16
- Next earnings
- —
About Neovacs S.A.
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.
- ISIN
- FR0014018EV4
- Founded
- 1993
- Listed since
- Apr 21, 2010
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.66 | +0.64% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.00 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €875.60 | -2.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $144.51 | -0.39% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.